According to a market report by Lucintel, the future of the global icosapent ethyl api market looks promising with opportunities in the cardiovascular disease management, hypertriglyceridemia treatment, post-myocardial infarction care, and diabetes management markets. The global icosapent ethyl api market is expected to reach an estimated $506 million by 2035 from $272 million in 2027 with a CAGR of 7.5% from 2027 to 2035. The major drivers for this market are the growing adoption of prescription-based lipid-lowering therapy, the rising healthcare expenditure across developing nation, and the increasing focus on prescription omega-3 product.
A more than 150-page report to understand trends, opportunity and
forecast in global icosapent ethyl api market to 2035 by product type (branded
icosapent ethyl products, generic icosapent ethyl products, combination therapy
products, and experimental formulations), distribution channel (hospitals &
clinics, retail pharmacies, online pharmacies, and healthcare institutions),
application (cardiovascular disease management, hypertriglyceridemia treatment,
post-myocardial infarction care, and diabetes management), end use (healthcare
professionals, patients, pharmaceutical companies, and research institutions),
and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the product type category, branded
icosapent ethyl products is expected to witness the highest growth over the
forecast period due to higher demand for branded icosapent ethyl products in
the field of cardiovascular care.
Within the application category, cardiovascular disease management is
expected to witness the highest growth over the forecast period due to rising
prevalence and increasing demand for treatment of Cardiovascular Diseases.
Download sample by clicking on icosapent ethyl api market.
In terms of regions, APAC is expected to witness the highest growth over
the forecast period due to rapid development of the healthcare infrastructure
and the increasing adoption of cardiovascular treatment across countries.
Chemport, DSM Nutritional Products, AK Biopharm, Huatai Pharma, Bizen
Chemical, Finorga SAS, Sichuan Gowell Pharmaceutical are the major suppliers in
the icosapent ethyl api market.
This
unique research report will enable you to make confident business decisions in
this globally competitive marketplace. For a detailed table of contents,
contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get
access of more than 1000 reports at fraction of cost visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
your growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Vein Recognition Module Market
Vending Machine Telemetry Market
Vibration Damping Module Market
No comments:
Post a Comment